Search research articles
Contact Us
Filters
Showing results (81-90 of 86) with videos related to
Page
of 9
Sort By:
You have reached the last page of results.
This site can display upto 86 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 30, 2016
Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR)
J Sehouli, R Chekerov, A Reinthaller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 25, 2020
Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)
P A Fasching, T Link, J Hauke, et al.
ESMO Open
|
April 25, 2024
Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)
P Meyer-Wilmes, J Huober, M Untch, et al.
Gastroenterology
|
June 24, 2020
Human Plasminogen Exacerbates Clostridioides difficile Enteric Disease and Alters the Spore Surface
Milena M Awad, Melanie L Hutton, Adam J Quek, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2018
Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto
S Loibl, K E Weber, K M Timms, et al.
Nature Communications
|
March 19, 2023
Integrative omics identifies conserved and pathogen-specific responses of sepsis-causing bacteria
Andre Mu, William P Klare, Sarah L Baines, et al.
Page
of 9
Search research articles
Search
Showing results (81-90 of 86) with videos related to
Sort By:
Page
of 9
You have reached the last page of results.
This site can display upto 86 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 30, 2016
Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR)
J Sehouli, R Chekerov, A Reinthaller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 25, 2020
Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)
P A Fasching, T Link, J Hauke, et al.
ESMO Open
|
April 25, 2024
Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)
P Meyer-Wilmes, J Huober, M Untch, et al.
Gastroenterology
|
June 24, 2020
Human Plasminogen Exacerbates Clostridioides difficile Enteric Disease and Alters the Spore Surface
Milena M Awad, Melanie L Hutton, Adam J Quek, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2018
Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto
S Loibl, K E Weber, K M Timms, et al.
Nature Communications
|
March 19, 2023
Integrative omics identifies conserved and pathogen-specific responses of sepsis-causing bacteria
Andre Mu, William P Klare, Sarah L Baines, et al.
Page
of 9